2. He says it appeared the authors ran entire paragraphs from press releases and websites about ivermectin and Covid-19 through a thesaurus to change key words.— BFM News (@NewsBFM) July 16, 2021
"The data was also terribly formatted, including a patient who left hospital on the non-existent date of 31/06/2020." pic.twitter.com/4GIMyHnSTk
4. "They claimed 4 patients died in their standard treatment group for mild & moderate Covid-19. According to the original data, it was 0.— BFM News (@NewsBFM) July 16, 2021
"In their ivermectin treatment group for severe Covid-19, they claimed 2 patients died, but the number in their raw data is 4," he says.
6. UK Guardian reports, Lawrence first became aware of the Elgazzar preprint paper when it was assigned to him by one of his lecturers for an assignment that formed part of his master's degree.— BFM News (@NewsBFM) July 16, 2021
Report by Jack Lawrence: https://t.co/RdLXPM0MoP
Huge study supporting ivermectin as Covid treatment withdrawn over ethical concerns https://t.co/mlInBhEZXx— Guardian Science (@guardianscience) July 15, 2021
Excellent forensic deep dive into the fraudulent Elgazzar et al Ivermectin in COVID study.— Nick Mark MD (@nickmmark) July 15, 2021
This analysis goes *DEEP* & identifies many flaws that are strong proof of data fabrication.
(🧐Nerdy aside: it even applies Benford’s law; one of my math favs)https://t.co/Ymqa0lt8Xi pic.twitter.com/Rn4BTACLPe
One problem with meta-analyses is that it is dependent on the underlying data. In this case, the largest IVM study included (n=400) conducted by Dr Ahmed Elgazzar from Benha University in Egypt appears to be fake and the pre-print has been withdrawn. https://t.co/kgmynddjI7 https://t.co/S40mtOPhxv— David Boulware, MD MPH (@boulware_dr) July 16, 2021
Phase 3 double-blind randomized clinical trials are needed to provide definitive data.— David Boulware, MD MPH (@boulware_dr) July 16, 2021
If you are in the USA and have a #COVID19 diagnosis within ❤ days, consider participating in Univ of Minnesota https://t.co/JqAM3WlXHa trial testing #ivermectin or #fluvoxamine or #metformin.
Still this blurs outpatient + inpatient studies, some of whom received steroids (or other therapies), generally not mentioned.— David Boulware, MD MPH (@boulware_dr) July 16, 2021
As stated before, some of this ~4.2% mortality benefit may likely be from treating Strongyloides in hospitalized COVID-19 patients receiving steroids in settings where the expected Strongyloides prevalence is 5-10%. Advice: https://t.co/UsjWcY4BeL— David Boulware, MD MPH (@boulware_dr) July 16, 2021